NBIX - Neurocrine Biosciences, Inc.

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Borg Warner, Boyd Gaming, JetBlue, Lattice Semiconductor, Lockheed Martin, Nike, Northrop Grumman, Procter & Gamble, SPX Technologies, and More

Pre-Market Stock Futures: Futures are trading higher after we started off the first full trading week of the undefined quarter in solid style, as all major indices finished the day higher despite interest rates continuing to tick higher. Technology led the way, and the tech-heavy Nasdaq responded, closing at 27,477, up 1.05% to a new

Oct 06, 2026 03:54 AM • 247wallst.com

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will capture caregiver-reported information to better understand the experience and burden of caring for someone with Prader-Willi syndrome Integrated analysis will further evaluate adverse events of special interest — including fluid retention, hyperglycemia, hirsutism and hypertrichosis — during VYKAT XR treatment SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and real-world evidence for VYKAT® XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference, taking place Oct. 7-10 in Philadelphia.

Sep 30, 2026 04:30 AM • prnewswire.com

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W.

Sep 28, 2026 12:05 PM • prnewswire.com

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit

Neurocrine Biosciences NASDAQ: NBIX outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company's efforts to diversify beyond its largest product, INGREZZA.

Sep 22, 2026 08:02 PM • marketbeat.com

Integrated Wealth Concepts LLC Sells 5,703 Shares of Neurocrine Biosciences, Inc. $NBIX

Integrated Wealth Concepts LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 41.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,041 shares of the company's stock after selling 5,703 shares during the period. Integrated Wealth Concepts

Sep 17, 2026 12:24 AM • defenseworld.net

Corient Private Wealth LP Buys 9,645 Shares of Neurocrine Biosciences, Inc. $NBIX

Corient Private Wealth LP increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 21.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,680 shares of the company's stock after purchasing an additional 9,645 shares during

Sep 16, 2026 11:32 PM • defenseworld.net

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sep 15, 2026 04:01 PM • seekingalpha.com

Engineers Gate Manager LP Increases Holdings in Neurocrine Biosciences, Inc. $NBIX

Engineers Gate Manager LP raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 64.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,361 shares of the company's stock after purchasing an additional 7,163 shares during the period.

Sep 14, 2026 12:25 AM • defenseworld.net

Amundi Has $37.16 Million Position in Neurocrine Biosciences, Inc. $NBIX

Amundi lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 8.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 220,463 shares of the company's stock after purchasing an additional 16,826 shares during the quarter. Amundi owned 0.22% of

Sep 10, 2026 11:39 PM • defenseworld.net

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 10, 2026 06:47 AM • seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Sep 09, 2026 02:17 PM • seekingalpha.com

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Continuum Advisory LLC

Continuum Advisory LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 99.1% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 418 shares of the company's stock after selling 43,650 shares during the period. Continuum Advisory LLC's holdings in Neurocrine Biosciences were

Sep 08, 2026 12:04 AM • defenseworld.net

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.

Sep 02, 2026 12:01 PM • prnewswire.com

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?

NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.

Aug 31, 2026 09:36 AM • zacks.com

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.

Aug 25, 2026 10:30 AM • zacks.com

B. Metzler seel. Sohn & Co. AG Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX

B. Metzler seel. Sohn and Co. AG acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,986 shares of the company's stock, valued at approximately $1,009,000. Other institutional investors and hedge

Aug 23, 2026 11:57 PM • defenseworld.net

Allworth Financial LP Invests $2.50 Million in Neurocrine Biosciences, Inc. $NBIX

Allworth Financial LP purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,853 shares of the company's stock, valued at approximately $2,503,000. A number of other hedge funds

Aug 21, 2026 11:07 PM • defenseworld.net

Neurocrine Biosciences: 'House Full Of Options'

Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a deep, diversified pipeline. Ingrezza anchors NBIX's profitability, with exclusivity until 2038 and projected peak sales of $3.3B, while Crenessity and Vykat XR add growth pillars. Valuation models yield $224/share (DCF) and $167/share (with all research costs), both above recent market prices, highlighting undervaluation.

Aug 21, 2026 10:57 PM • seekingalpha.com

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?

NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.

Aug 20, 2026 08:26 AM • zacks.com

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?

Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.

Aug 20, 2026 08:21 AM • zacks.com

Neurocrine price target lowered to $214 from $231 at UBS

$214.00 (was $140.44)

UBS

Sep 29, 2026 06:12 AM • TheFly

Neurocrine price target raised to $183 from $182 at Morgan Stanley

$183.00 (was $156.57)

Morgan Stanley

Sep 11, 2026 07:55 AM • TheFly

RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'

$198.00 (was $155.66)

Brian Abrahams · RBC Capital

Sep 08, 2026 09:15 AM • StreetInsider

Neurocrine price target lowered to $218 from $221 at Bernstein

$218.00 (was $156.49)

Bernstein

Aug 13, 2026 07:56 AM • TheFly

Neurocrine price target lowered to $182 from $196 at Morgan Stanley

$182.00 (was $156.49)

Morgan Stanley

Aug 13, 2026 07:36 AM • TheFly

Neurocrine price target lowered to $165 from $190 at Deutsche Bank

$165.00 (was $156.49)

Deutsche Bank

Aug 13, 2026 04:26 AM • TheFly

Neurocrine price target raised to $194 from $185 at Wedbush

$194.00 (was $170.06)

Wedbush

Aug 03, 2026 08:18 AM • TheFly

H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX)

$215.00 (was $166.80)

Andrew Fein · H.C. Wainwright

Aug 03, 2026 06:54 AM • StreetInsider

Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord

$210.00 (was $166.80)

Sumant Kulkarni · Canaccord Genuity

Aug 03, 2026 06:41 AM • StreetInsider

Neurocrine price target raised to $196 from $193 at Morgan Stanley

$196.00 (was $167.38)

Morgan Stanley

Jul 31, 2026 09:05 AM • TheFly

Neurocrine price target raised to $190 from $170 at Deutsche Bank

$190.00 (was $165.93)

David Hoang · Deutsche Bank

Jul 31, 2026 08:54 AM • TheFly

Neurocrine price target raised to $204 from $200 at Needham

$204.00 (was $185.50)

Needham

Jul 31, 2026 07:45 AM • TheFly

Neurocrine price target raised to $210 from $207 at Piper Sandler

$210.00 (was $185.50)

GAAP EPS · Piper Sandler

Jul 31, 2026 07:34 AM • TheFly

Neurocrine price target raised to $225 from $186 at Baird

$225.00 (was $185.50)

Brian Skorney · Robert W. Baird

Jul 31, 2026 07:21 AM • TheFly

Neurocrine price target raised to $222 from $200 at Guggenheim

$222.00 (was $185.50)

Guggenheim

Jul 31, 2026 06:51 AM • TheFly

Neurocrine price target raised to $200 from $175 at Guggenheim

$200.00 (was $178.10)

Guggenheim

Jul 21, 2026 08:01 AM • TheFly

Neurocrine price target raised to $200 from $175 at Wells Fargo

$200.00 (was $171.55)

Wells Fargo

Jul 17, 2026 06:23 AM • TheFly

Neurocrine price target raised to $200 from $155 at Truist

$200.00 (was $175.16)

Truist Financial

Jul 13, 2026 09:52 AM • TheFly

Neurocrine price target raised to $170 from $144 at BMO Capital

$170.00 (was $173.89)

BMO Capital

Jul 13, 2026 08:20 AM • TheFly

Neurocrine price target raised to $185 from $176 at Wedbush

$185.00 (was $173.73)

Wedbush

Jul 13, 2026 08:05 AM • TheFly